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Melatonin exerts oncostatic effects on different kinds of neoplasias, especially on oestrogen-dependent tumours. Recently, it has been
described that melatonin, on the basis of its antioxidant properties, inhibits the growth of glioma cells. Glioma cells express oestrogen
receptors and have the ability to synthesise oestrogens from androgens. In the present study, we demonstrate that pharmacological
concentrations of melatonin decreases the growth of C6 glioma cells and reduces the local biosynthesis of oestrogens, through the
inhibition of aromatase, the enzyme that catalyses the conversion of androgens into oestrogens. These results are supported by three
types of evidence. Firstly, melatonin counteracts the growth stimulatory effects of testosterone on glioma cells, which is dependent on
the local synthesis of oestrogens from testosterone. Secondly, we found that melatonin reduces the aromatase activity of C6 cells,
measured by the tritiated water release assay. Finally, by (RT)–PCR, we found that melatonin downregulates aromatase mRNA
steady-state levels in these glioma cells. We conclude that melatonin inhibits the local production of oestrogens decreasing aromatase
activity and expression. By analogy to the implications of aromatase in other forms of oestrogen-sensitive tumours, it is conceivable
that the modulation of the aromatase by pharmacological melatonin may play a role in the growth of glioblastomas.
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The role of melatonin in tumour development has been under
intensive study during the last few decades. It has been reported
that melatonin inhibits tumour growth in a variety of in vivo and
in vitro experimental models of neoplasia (Cos and Sa ´nchez-
Barcelo ´, 2000a,b; Blask et al, 2002). The oncostatic actions of
melatonin have been demonstrated at length on hormone-
dependent tumours and especially on oestrogen-dependent breast
cancer (Sa ´nchez-Barcelo ´ et al, 2003, 2005). Experimental manip-
ulations activating the pineal gland, or the administration of
melatonin, reduce the incidence and growth rate of chemically
induced mammary tumours in rodents, while pinealectomy or
situations which implicate a reduction of melatonin production
usually stimulate mammary carcinogenesis (Cos and Sa ´nchez-
Barcelo ´, 2000a,b; Cos et al, 2006a). Melatonin reduces the
oestrogen-mediated development of breast cancer on the basis of
two different mechanisms: indirectly, by the downregulation of the
neuroendocrine reproductive axis and the consequent reduction of
pituitary and gonadal hormones responsible for the normal and
pathological growth of the mammary gland, and, on the other
hand, by a direct interaction with the oestrogen-response pathway
at the tumour cell level (Cos et al, 1998; Sa ´nchez-Barcelo ´ et al,
2005). It has been demonstrated that melatonin counteracts the
effects of oestrogens on mammary tumoral cells, thus behaving as
a selective oestrogen receptor modulator (SERM). Furthermore,
melatonin regulates the expression and activity of the aromatase,
the main enzyme responsible for the local synthesis of oestrogens,
thus behaving as a selective oestrogen enzyme modulator (SEEM)
(Cos et al, 1991, 2006a; Martı ´nez-Campa et al, 2005).
Oestrogens have well-known cytoprotective effects in neural
cells and it has been reported to also have biological effects on glial
cells, although these have been less studied (Shy et al, 2000; Sur
et al, 2003; Haghighat et al, 2004; Mhyre et al, 2006; Sribnick et al,
2006). Glioblastoma is the most frequent primary malignant CNS
tumour in adults. These tumours express oestrogen receptor and
also express aromatase (Jung-Testas et al, 1992, 1994; Yague et al,
2004). Expression of aromatase in the brain is involved in the
regulatory effects of androgens, via its conversion into oestrogens,
on neural differentiation, maturation, neural plasticity, neuro-
endocrine functions and sexual behaviour (Lephart, 1996). There
is some evidence that tamoxifen, one of the oestrogen receptor
modulators most frequently used for treatment and also for
prevention of breast cancer, arrests the growth of some glio-
blastomas and it has neuroprotective actions (Shy et al, 2000).
Proliferative signal transduction in glioma cells occurs predomi-
nantly through a protein kinases C-dependent pathway, and
tamoxifen has been demonstrated to be effective in blocking cell
growth in glioma cell lines by inhibiting these protein kinases C
(Baltuch and Yong, 1996; Luo et al, 1997; Bergan et al, 1999).
Melatonin has been shown to have neuroprotective effects in a
large number of different experimental models (Cos et al, 1996;
Armstrong and Niles, 2002; Feng and Zhang, 2004; Rinco ´n Castro
et al, 2005; Martı ´n et al, 2006; Herrera et al, 2007). However, there
is limited evidence suggesting that melatonin may affect glio-
blastoma growth. In a clinical trial in which melatonin was
administered to patients being treated with radiation therapy for
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sglioblastoma, a significant increase in 1-year survival was seen
(Lissoni et al, 1996). C6 glioma cells express both of the protein-
coupled melatonin receptor subtypes, MT1 and MT2 and when they
are treated with physiological or higher concentrations of
melatonin, a significant induction of relative glial cell line-derived
neurotrophic factor has been detected (Armstrong and Niles,
2002). This finding has suggested that induction of the glial cell
line-derived neurotrophic factor is involved in physiological
neuroprotection by melatonin. High doses of valproic acid, a
potent antiepileptic, induce both upregulation of melatonin
receptors and expression of neurotrophic factors in C6 glioma
cells (Rinco ´n Castro et al, 2005). Recently, it has been reported that
melatonin at millimolar concentrations reduces, both in vitro and
in vivo, the growth of C6 glioma cells (Martı ´n et al, 2006). This
inhibition has been associated with a decrease in basal levels of
intracellular free radicals. In addition to the beneficial effects of
providing direct antioxidant protection to glioma cells, melatonin
may enhance neuroprotection against Ab-induced neurotoxicity
by attenuating Ab25-35 or Ab1-42-induced apoptosis and promot-
ing the survival of glial cells (Feng and Zhang, 2004).
Although C6 glioma cells express both oestrogen receptor
and aromatase and have, therefore, the possibility to produce
oestrogens from androgen precursors, which may act as paracrine
or autocrine factors to promote tumour cell growth, the
significance of this fact is not very well determined. In other
oestrogen-dependent tumours, such as mammary tumours, the
inhibition of aromatase activity by aromatase inhibitors is
currently one of the first therapeutic strategies used against
the growth of these tumours (Kitawaki et al, 1992; Burak et al,
1997). Since melatonin inhibits the growth of C6 cells, and this
indoleamine has been demonstrated to be able to decrease
aromatase expression and activity in other tumour cell lines, our
objective in the present study was to analyse the possible effects of
melatonin on the local synthesis of oestrogens in C6 glioma cells
and its influence on the cell proliferation.
MATERIALS AND METHODS
Chemicals
Unless otherwise indicated, all chemicals used in this work were
purchased from Sigma-Aldrich (Madrid, Spain).
Cells and culture conditions
Rat glioma cells (C6) were a kind gift from Dr Carmen Rodrı ´guez
from the Department of Structural and Cellular Biology of the
University of Oviedo (Spain). They were maintained as monolayer
cultures in 75cm
2 plastic culture flasks in Dulbecco’s modified
Eagle’s medium (DMEM)/HAM’s nutrient mixture F-12 supple-
mented with 10% fetal bovine serum (FBS) (PAA Laboratories
GmdH, Pusching, Austria), 20Uml
 1 penicillin and 20mgml
 1
streptomycin, at 371C in a humid atmosphere containing 5% CO2.
Cells were subcultured every 3–4 days by suspension in 5mM
Na2-EDTA in PBS (pH 7.4) at 371C for 5min.
Before each experiment, stock subconfluent monolayers (80%)
of glioma cells were incubated with 5mM Na2-EDTA in PBS (pH
7.4) at 371C for 5min, re-suspended in DMEM/HAM F12 mixture
supplemented with 10% FBS and passed repeatedly through a 25-
gauge needle to produce a single cell suspension. Cell number and
viability were determined by staining a small volume of cell
suspension with 0.4% Trypan blue saline solution and examining
the cells in a haemocytometer.
Measurement of cellular proliferation
Glioma cells were seeded in 96-multiwell plates at a density of 4000
cells per well, in DMEM/HAM F12 mixture with 10% FBS,
20Uml
 1 penicillin and 20mgml
 1 streptomycin, at 371Ci na
humid atmosphere containing 5% CO2. After 24h of incubation to
allow a correct attachment of the cells, media were renewed
containing either 1mM,1 0mM,1mM, 100nM,1n M,1 0p M melatonin
and/or 10nM oestradiol and/or the diluent of these drugs (ethanol,
at final concentration lower than 0.0001% per plate). Cells were
cultured for 3 or 4 days. Cell proliferation was measured by the
MTT method reading absorbance at 570nm in a microplate reader.
Indirect measurement of aromatase activity
Indirect evidence of aromatase activity of C6 glioma cells was
obtained by evaluating cell proliferation in oestrogen-free media in
the presence of testosterone. C6 glioma cells were seeded into
96-well culture plates at a density of 4000 cells per well, in DMEM/
HAM F12 mixture supplemented with 10% FBS, 20Uml
 1
penicillin 20mgml
 1 streptomycin, at 371C in a humid atmosphere
containing 5% CO2. After 24h of incubation, media were changed
to others supplemented with 5% charcoal-stripped FBS (sFBS)
containing either 1mM testosterone, 1mM melatonin, 100mM
aminoglutethimide (an aromatase inhibitor), or the diluent of
these drugs (ethanol, at final concentration lower than 0.0001% per
plate). Cell proliferation was assessed at 3 and 4 days of culture, by
using the MTT method, reading absorbance at 570nm in a
microplate reader.
Direct measurement of cellular aromatase activity
Aromatase activity in C6 glioma cells was measured by the tritiated
water release assay, based on the formation of tritiated water
during aromatisation of an androgenic substrate such as
[1b-
3H(N)]-androst-4-ene-3,17-dione (Ackerman et al, 1981).
Glioma cells were seeded onto 60 15mm tissue culture dishes
(2 10
6 cells per dish) in DMEM/HAM F12 mixture supplemented
with 10% FBS, 20Uml
 1 penicillin and 20mgml
 1 streptomycin.
After 24h, when a homogeneous monolayer of preconfluent C6
cells was reached, media were aspirated and replaced by fresh
media (1ml per plate) supplemented with 5% sFBS and containing
100nM [1b-
3H(N)]-androst-4-ene-3,17-dione] (NEN Life Science
Products, Boston, MA, USA) (25–30CimM
 1) in the presence
of 1mM,1mM or 1nM melatonin or its diluent (ethanol at a final
concentration lower than 0.0001%). At 24h of incubation, the
culture dishes were placed on ice for 15min to condense any water
vapour and the media were transferred to tubes containing 0.25ml
ice-cold 30% trichloroacetic acid (wtvol
 1), vortexed and
centrifuged at 1700g for 15min. The supernatants were extracted
with chloroform, vortexed, set at room temperature for 10min and
then centrifuged at 1700g for 15min. The resulting aqueous
supernatants were adsorbed with 10% dextran-coated charcoal,
vortexed, centrifuged at 1700g for 15min and the supernatant
added to vials with scintillation cocktail and counted in a beta
counter. The amount of radioactivity in water [
3H] measured was
corrected by subtracting the blank values from each sample,
obtained by incubating dishes containing medium with the
tritiated androgen but no cells. The values were also corrected
by taking into account the fractional retention of tritium in
medium water throughout the procedure of incubation and
processing, utilising parallel dishes containing medium plus
known amounts of [
3H] water (NEN Life Science Products)
through incubation and assay. The fractional retention of tritium
in medium water throughout the incubation and processing of
samples was always higher than 85%.
Measurement of aromatase mRNA expression
Analysis of the aromatase mRNA expression in C6 glioma cells was
carried out by real-time reverse transcription (RT)–PCR. The total
cellular RNA was purified with the Nucleospin RNA II Kit
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s(Macherey-Nagel, Du ¨ren, Germany) following the manufacturer’s
instructions. Integrity of RNA was assessed by electrophoresis in
ethidium bromide-stained 1.2% agarose-Tris-borate EDTA gels.
The absorbance ratio A260nm/A280nm was greater than 1.8. For
cDNA synthesis, 1mg of total RNA was denaturated at 651C for
10min and reverse-transcribed 50min at 451C with cDNA
Synthesis kit (Bioline, London, UK) in a final volume of 20mli n
the presence of 500ng of oligo (dT)12–18 primer.
PCR was performed using a set of rat aromatase-specific primers
(50–TATTGGAAATGCTGATTGCGG (forward) and 50-TTGGGC
TTGGGGAAATACTCG (reverse)) (Sigma Genosys Ltd, Cambridge,
UK). The coding sequence between the two PCR primer sites is
interrupted by three introns in the gene. As a control quantifica-
tion, S14 mRNA was also carried out by RT–PCR using a set
of specific primers (50-TCACCGCCCTACACATCAAAC (forward) and
50-TCCTGCGAGTGCTGTCAGAG (reverse)) (Sigma Genosys Ltd).
Real-time PCRs were performed in a MX3000 (Stratagene,
La Jolla, CA, USA) using Brilliant
s SYBR
s Green PCR Master Mix
(Stratagene) following the manufacturer’s instructions. Amplifica-
tions were performed for 40 cycles using the following temperature
profile: 551C, 60s (annealing); 721C, 30s (extension); and 951C,
30s (denaturation).
Statistics
The data on cell proliferation or aromatase activity and expression
are expressed as the mean7s.e.m. Statistical differences between
groups were processed by one-way analysis of variance (ANOVA)
followed by the Student–Newman–Keuls test.
RESULTS
Incubation with 17b-oestradiol (10nM) significantly stimulated
the proliferation of C6 cells (Figure 1). The simultaneous addition
of 17b-oestradiol and melatonin resulted in a significantly
(Po0.001) lower cell proliferation than that of the 17b-oestra-
diol-treated cells and control (untreated) cells. Melatonin 1mM
and 1nM were not able to counteract the stimulatory effects of
17b-oestradiol (Figure 1).
Indirect evidence of aromatase activity of glioma cells was
obtained by evaluating cell proliferation in oestrogen-free media in
the presence of testosterone. Testosterone (10mM) significantly
increased proliferation of C6 cells cultured for 4 days in media with
sFBS (Figure 2). This stimulatory effect was reduced (Po0.001) by




































































Figure 1 Effects of melatonin (1mM,1mM and 1nM) and oestradiol (10nM), either alone or in combination, on C6 glioma cells proliferation. Cells were
seeded into 96-well culture plates (4000 cells per well) in medium supplemented with 10% fetal bovine serum (FBS) for 24h. Then the media were
aspirated and replaced by fresh media supplemented with 5% charcoal-stripped FBS (sFBS) and containing the indicated concentrations of oestradiol and/or
melatonin. After 4 days, cell proliferation was measured by the MTT method. Data are expressed as the percentage of the control group (mean7s.e.m.). a,
Po0.05 vs control; b, Po0.001 vs control; c, Po0.001 vs oestradiol 10nM;d ,Po0.05 vs oestradiol 10nM;e ,Po0.05 vs melatonin 1mM.













































Figure 2 Indirect measurement of aromatase activity. Effects of 1mM
testosterone (T), 1mM melatonin (M), 100mM aminoglutethimide (A), or
the diluent of these drugs (ethanol 0.0001%) (C), either alone or in
combination on glioma cell proliferation. Cells were seeded into 96-well
culture plates (4000 cells per well) in medium supplemented with fetal
bovine serum (FBS) for 24h and subsequently for 4 days in medium
supplemented with charcoal-stripped FBS (sFBS) containing the above-
mentioned drugs. Data are expressed as the percentage of the control
group (mean7s.e.m.). a, Po0.01 vs C; b, Po0.001 vs C; c, Po0.001 vs T; d,
Po0.001 vs A; e, Po0.001 vs M; f, Po0.001 vs TA; g, Po0.001 vs TM.
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sleast in part, cell proliferation was dependent on the formation of
oestrogens from testosterone by the aromatase activity of the cells.
Melatonin (1mM) was also able to counteract the stimulatory effect
of testosterone to values below those obtained with amino-
glutethimine, thus suggesting that it also exerts inhibitory effects
on aromatase (Figure 2).
The aromatase activity of C6 glioma cells incubated for 24h with
tritiated androstenedione was estimated by the formation of
tritiated water. Figure 3 shows that only melatonin 1mM
significantly decreases aromatase activity of C6 cells. Melatonin
1m M induced a significant 40% inhibition of the aromatase activity
of glioma cells.
To determine whether this inhibitory effect of melatonin over
aromatase activity was due to a downregulation of the aromatase
expression at the transcriptional level, we then incubated glioma
cells with either melatonin (1mM,1 mM or 1nM) or vehicle for
90min and total RNA was isolated to perform real-time PCRs with
specific primers for rat aromatase. As a control, the same samples
were subjected to real-time PCR with specific primers for S14, a
ribosomal protein component of the 40S subunit. Melatonin
treatment significantly inhibited (Po0.01) aromatase mRNA
expression in glioma cells at 1mM concentration (Figure 4).
DISCUSSION
Sex hormones play a multifaceted role throughout the body. Sex
differences in brain tumour incidence suggest that hormonal
factors may play a role in the aetiology of this type of tumour and
there is evidence that hormones related to female reproductive
function may be associated with brain cancer risk (Huang et al,
2004). The incidence of glioma is 1.5 times greater in men than in
women and it has been described an inverse relationship between
younger age at menarche (among postmenopausal women),
cumulative number of menstrual cycles over the lifetime, fewer
months of breast-feeding and the use of hormone-replacement
therapy and the risk for glioma (Inskip et al, 1995; Huang et al,
2004). Steroids or their precursors can be metabolised in the CNS
to derivates which can affect brain function and may have an
important clinical significance (Weidenfeld and Schiller, 1984).
Previous studies have shown that human brain and human
neuronal cell lines secrete oestrogens (Stoffel-Wagner, 2001, 2003).
Melatonin, the main pineal hormone, inhibits the growth of C6
rat glioma cells both in vitro and in vivo, and this inhibition has
been related with the antioxidant abilities of this indolamine
(Martı ´n et al, 2006). In other models of oestrogen-sensitive
tumours, such as breast cancer, melatonin oncostatic actions
seem to be mainly based on its interaction with the tumour
cells’oestrogen-response pathway (Cos and Sa ´nchez-Barcelo ´,
2000a,b; Del Rio et al, 2004; Cos et al, 2006a). Melatonin interacts
with oestradiol at the oestrogen receptors level in the mammary
tumour cell and also regulates the expression and the activity of
the aromatase responsible for the local synthesis of oestrogens.
Thus, a single molecule has both SERM and SEEM properties, one
of the main objectives desired for the breast antitumour drugs
(Cos et al, 2005, 2006a,b; Martı ´nez-Campa et al, 2005). For that
reason, we decided to address whether the modulation of the local
biosynthesis of oestrogens could be involved in the inhibition of
C6 glioma cells by melatonin.
According to previous findings (Martı ´n et al, 2006), only 1mM
melatonin added to the culture decreased C6 cell growth. This
melatonin concentration reduced C6 growth by 30% after 4 days of
culture. In the same way, also high concentrations of melatonin are
also necessary to obtain oncostatic actions in neuroblastoma cells
and other kinds of tumour cells (Sainz et al, 2005; Garcı ´a-Santos
et al, 2006). Melatonin is a highly lipid-soluble indolamine which
may easily cross the blood–brain barrier, and there is evidence
that melatonin concentration in the cerebrospinal fluid is higher
than in blood (Rousseau et al, 1999; Longatti et al, 2007). These
high concentrations of melatonin in the cerebrospinal fluid may
contribute to explain why high levels of melatonin are necessary to
inhibit glioblastoma cell proliferation.
Oestrogen receptors present in primary glial cell cultures and
different types of glial cells (Jung-Testas et al, 1992; Santagati et al,
1994; Yague et al, 2004) allow this non-neuronal cells of the CNS to
respond to oestrogens; so glioma cells were able to respond
significantly to oestradiol in the culture. Melatonin, only at 1mM
concentration, counteracted the growth stimulatory effect of
oestradiol on C6 cells. In addition, previous studies have













































Figure 3 Effects of melatonin (1mM,1 mM or 1nM) or the diluent
(ethanol at 0.0001% final concentration) on aromatase activity of glioma
cells. Cells were seeded onto 60 15mm dishes (2 10
6 cells per dish) in
Dulbecco’s modified Eagle’s medium (DMEM)/HAM F12 mixture supple-
mented with 5% FBS for 24h. Then, media were aspirated and replaced by
fresh media supplemented with 5% charcoal-stripped FBS (sFBS) and
containing tritiated androstenedione and the indicated concentrations of
melatonin. Aromatase activity was determined after 24h of incubation, as
described in Materials and Methods. Data are expressed as the percentage




















































Figure 4 Effects of melatonin on the expression of aromatase mRNA in
glioma cells. Cells were incubated with melatonin (1mM,1mM or 1nM)o r
ethanol (0.0001%; control) for 90min. Total mRNA was isolated from C6
cells and reverse transcribed. cDNA was subjected to PCR using specific
primers for P450 aromatase or S14. Data are expressed as the percentage
of the control group (mean7s.e.m.). a, Po0.01 vs control; b, Po0.05 vs
melatonin 1mM.
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sglioma cell lines express aromatase and, are, therefore, capable of
producing oestrogens from androgens (Stoffel-Wagner, 2001;
Yague et al, 2004).
The present study demonstrates that melatonin, at 1mM
concentration, reduces the synthesis of oestrogens in C6 glioma
cells, through the inhibition of aromatase, the enzyme that
catalyses the rate-limiting step in the conversion of androgens
into oestrogens (Zhou et al, 1993). These results are supported by
the three types of experiments we carried out. In the first
experimental series, we demonstrate that melatonin counteracts
the growth stimulatory effects of testosterone on C6 glioma cells
(Merritt and Foran, 2007) cultured in oestrogen-free media. Under
these conditions, cell growth depends on the biotransformation of
androgens to oestrogens via their own aromatase activity.
Consequently, the inhibitory effects of melatonin could be
explained because of its antiaromatase activity. In a second series
of experiments, we directly quantified the aromatase activity of
glioma cells, finding that this was reduced by melatonin at 1mM
concentration, the same concentration that causes the greatest
antiproliferative effects in these cells (Martı ´n et al, 2006). Finally,
we demonstrated that 1mM melatonin induced a remarkable
decrease in the expression of mRNA aromatase of C6 glioma cells.
To our knowledge this is the first time that the influence of
melatonin on aromatase expression and activity of glioblastoma
cells has been established. In fact, the antiaromatase activity of
melatonin in other cells has not been firmly established until
recently. A limited number of earlier studies had brought
controversial results. Thus, no consistent effects of melatonin on
aromatase activity were described in human, porcine or bovine
granulose cells cultured in a serum-supplemented medium
(Webley and Luck, 1986; Tanavde and Maitra, 2003). Other
authors attributed the low sperm quality of human seminal plasma
to a low aromatase activity dependent on high endogenous
melatonin levels (Yie et al, 1991) or long-term melatonin
administration (Luboshitzky et al, 2002). A reduction in the
aromatase activity in the hypothalamic–preoptic area of
adult male Syrian hamsters chronically treated with melatonin
(Petterborg et al, 1991) has also been described, but considered
secondary to the decreased circulating levels of testosterone. It was
our group that recently described, in the first instance, that
melatonin works as a SEEM in breast cancer cells (in vitro) as well
as in DMBA-induced rat mammary tumours (in vivo) (Cos et al,
2005, 2006b).
Our results indicate that oestrogens locally produced by
aromatase in glioblastoma cells may act as autocrine or paracrine
factors and melatonin is able to inhibit this local production of
oestrogens by decreasing aromatase activity and expression. The
significance of this melatonin action on aromatase in glioblastoma
needs to be determined. There is little information about the
capacity of C6 glioma cells to growth in the presence of aromatase
inhibitors; however, by analogy to the implications of aromatase in
other forms of oestrogen-sensitive tumours, such as breast
tumours, it is conceivable that the modulation of the activity and
expression of aromatase by pharmacological concentrations of
melatonin may play a role in the growth of glioblastomas.
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